Regeneron Pharmaceuticals is acquiring most of 23andMe’s assets to support its genetics research and drug discovery efforts. The deal raises ongoing privacy concerns regarding the handling and protection of sensitive genetic data, impacting #Regeneron #23andMe #ConsumerData.
Keypoints
- Regeneron is purchasing $256 million worth of 23andMe’s core assets amid bankruptcy proceedings.
- The acquisition includes genetic testing services, a genetic biobank, and research assets, excluding Lemonaid Health.
- Regeneron commits to maintaining 23andMe’s existing privacy policies and user consent protocols.
- The deal is subject to court and regulatory approvals, with a court hearing scheduled for June 17, 2025.
- Privacy advocates express concerns over data security and consumer trust despite Regeneron’s assurances.
Read More: https://thecyberexpress.com/regeneron-acquire-23andme/